RORC and neoplasm: In more recent studies, Chrystal M. Paulo' laboratory demonstrated that using RORγ agonist LYC-55716 ex vivo or β-catenin and p110δ inhibitors augments the antitumor activity of murine tumor-specific Th17 cells (39, 69).